Thermopylae Holdings Ltd. bought $742K of AbCellera Biologics (ABCL)
Executed Mar 11 2025, disclosed Mar 11 2025, the same day.
Over the 21 trading sessions from the disclosed entry session (Mar 11 2025), the stock returned -13.1% (delay-adjusted); from the execution session (Mar 11 2025), -13.1%. Derived: entry at the session's open, exit at the close 20 sessions later.
Thermopylae Holdings Ltd. (10% owner) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in AbCellera Biologics Inc. (ABCL). Across 2 priced purchase filings, the average 21-session return was +0.0% from execution and -5.2% from disclosure (delay-adjusted; derived). The largest single filing was $580K of ABCL (177,457 sh × $3.27, as filed), executed Feb 26.
Healthcare · AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the Unit…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→38,000 sh × $3.44
Exec Feb 27
Filed Mar 2 · 2:16 PM ET ABCLPURCHASE AbCellera Biologics Inc. $580K
177,457 sh × $3.27
Exec Feb 26
Filed Feb 27 · 4:20 PM ET